How many generic drugs in China lack of competitive products?

"Recently, the FDA of the United States issued two important measures to increase generic competition and help low-cost generic drugs enter the market: first, release the list of brand drugs whose patents have been approved and whose monopoly period has expired; second, revise the Anda review priority procedure policy manual again." Why does FDA encourage generic competition? Too many patients are being priced out of the medicines they need While FDA doesn’t have a direct role in drug pricing, we can take steps to help address this problem by facilitating increased competition in the market for pres cription drugs through the approval of lower-cost, Too many patients cannot get the medicine they need because of the high price of the medicine Although FDA can't play a direct role in drug pricing, we can help solve this problem by approving low-cost generic drugs to promote the market competition of prescription drugs   Over the last decade alone, competition from safe and effective generic drugs has saved the health care system a bout $1.67 trillion When generics are dispensed at the pharmacy, the immediate savings to each of us are clear We could see even greater cost savings if we helped more safe and effective generic drugs get to market sooner, after patent and statutory exclusivity periods have lapsed, by addressing some of the scientific and regulatory obstacles to generic competition across the full range of FDA-approved drugs These barriers may delay and, in some cases, Only in the past decade, the competition from safe and effective generic drugs has saved $1.67 trillion for the health care system When generic drugs are distributed in pharmacies, the direct savings for each of us are clear If we can help more safe and effective generic drugs enter the market faster after the patent and legal monopoly period by solving some scientific and regulatory barriers of generic drug competition within the scope of FDA approved drugs, we can see larger cost savings These barriers can be delayed and, in some cases, may eventually prevent patients from getting more affordable drugs ——Dr Scott Gottlieb at present, there is a lack of competitive products in domestic generic drugs According to the database of drug intelligence screening system, there are 2595 kinds of chemical drugs belonging to exclusive varieties in China, including 752 varieties entering the medical insurance catalogue; 226 kinds of biological products belonging to exclusive varieties, including 53 varieties entering the medical insurance catalogue How to select the lack of generic competitive products through the pharmaceutical intelligence data? The screening conditions of the database of drug intelligence listing drug screening system are: imported domestic, drug category, medical insurance drug, drug dosage form, drug classification, number of same product, number of same product regulations and import classification In order to screen generic drugs in a disease field, we need to start from four aspects: imported domestic drugs, drug category, drug classification and the number of the same product, distinguish domestic drugs and imported drugs by importing domestic drugs; differentiate drugs and biological drugs by drug category; master a disease field by drug classification; select exclusive varieties from the number of the same product to And 2-3 kinds of manufacturers, so as to screen out the drug varieties that we want are lack of competitive products For example: we select the exclusive varieties of Chinese diabetes drugs, and we get the lack of varieties of diabetes drugs through the following selection According to the data, there are 30 kinds of exclusive chemicals for diabetes produced by domestic enterprises, as shown in the table below: